<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of fatigue in palliative care</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of fatigue in palliative care</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of fatigue in palliative care</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eduardo Bruera, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sriram Yennurajalingam, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas J Smith, MD, FACP, FASCO, FAAHPM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane Givens, MD, MSCE</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H29611029"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Fatigue is a common symptom in palliative care patients with serious and/or life-threatening illnesses. Fatigue has substantial adverse physical, psychosocial, and economic consequences for both patients and caregivers. However, due to its subjective nature and multidimensional causes, assessment and treatment of fatigue in the palliative settings can be complex.</p><p>This topic review will provide an overview of the clinical evaluation and treatment of fatigue in palliative care. A more extensive discussion of fatigue in patients with cancer and of the assessment and management of chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), is presented elsewhere. Most of the evidence presented in this topic relates to studies in cancer patients receiving palliative care. However, similar principles might apply to fatigue in patients with other end-stage conditions, although there are limited studies to better define the role of the described fatigue treatments in those patients. (See  <a class="medical medical_review" href="/d/html/2802.html" rel="external">"Cancer-related fatigue: Prevalence, screening, and clinical assessment"</a> and  <a class="medical medical_review" href="/d/html/2813.html" rel="external">"Cancer-related fatigue: Treatment"</a> and  <a class="medical medical_review" href="/d/html/2740.html" rel="external">"Clinical features and diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome"</a> and  <a class="medical medical_review" href="/d/html/2742.html" rel="external">"Treatment of myalgic encephalomyelitis/chronic fatigue syndrome"</a>.)</p><p class="headingAnchor" id="H29611044"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>Fatigue can be broadly defined as “a subjective state characterized by feelings of tiredness and a perception of decreased capacity for physical or mental work” [<a href="#rid1">1</a>]. The National Comprehensive Cancer Network defines cancer related fatigue as a “distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to activity and that interferes with usual functioning” [<a href="#rid2">2</a>]. The terms “asthenia” and “weakness” are often used in the same context. (See  <a class="medical medical_review" href="/d/html/2802.html" rel="external">"Cancer-related fatigue: Prevalence, screening, and clinical assessment", section on 'Definition'</a>.)</p><p>Fatigue should be distinguished from other common presentations in palliative care, including depression, delirium, drowsiness, demoralization, psychomotor retardation, and muscle weakness. Demoralization can be identified using a demoralization scale<strong> </strong>[<a href="#rid3">3,4</a>]. Psychomotor retardation involves a slowing down of thought and a reduction of physical movements, while muscle weakness describes a of lack of motor strength.</p><p class="headingAnchor" id="H29611051"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>Fatigue is a common symptom in palliative care patients who have serious and/or life-threatening illnesses, although it may be underreported and undertreated [<a href="#rid5">5-7</a>]. The prevalence of fatigue in patients with cancer ranges from 48 to 75 percent and increases to 85 percent in patients with serious and/or life-threatening illnesses [<a href="#rid8">8-10</a>]. Fatigue is especially prevalent patients with end-stage heart failure or nonmalignant chronic lung disease, such as chronic obstructive pulmonary disease (COPD). (See  <a class="medical medical_review" href="/d/html/110747.html" rel="external">"Palliative care for patients with advanced heart failure: Decision support and management of symptoms", section on 'Fatigue'</a> and  <a class="medical medical_review" href="/d/html/86307.html" rel="external">"Palliative care for adults with nonmalignant chronic lung disease", section on 'Other symptoms in chronic lung disease'</a>.)</p><p class="headingAnchor" id="H4310459"><span class="h1">ETIOLOGY</span></p><p class="headingAnchor" id="H2506150583"><span class="h2">Multiple causes likely</span><span class="headingEndMark"> — </span>Among patients with serious and/or life-threatening illness, fatigue can be distinguished as acute (as caused by an acute illness, such as infection or cardiac decompensation) or chronic, as in most cancer-related causes. Possible contributors to fatigue in patients with advanced cancer are outlined in the table (<a class="graphic graphic_table graphicRef98133" href="/d/graphic/98133.html" rel="external">table 1</a>). Some of the common treatable causes of fatigue in cancer patients at the end of life include deconditioning, infection, dehydration, metabolic and endocrine disorders, and cancer-related symptoms such as pain, anorexia, insomnia, and psychological symptoms [<a href="#rid3">3,4</a>]. In palliative care patients, fatigue may have multiple causes including pain, dyspnea, anorexia, psychological symptoms, gastroparesis symptoms (such as upper abdominal discomfort, bloating, and abdominal distension), and constipation [<a href="#rid11">11-14</a>]. Other major contributors are anemia and medications. In patients at the end of life, fatigue is typically multifactorial, with additional contributions from psychological symptoms such as anxiety and depression, cachexia, physical inactivity, infection, and hypogonadism. Fatigue related to cancer treatment is discussed separately. (See  <a class="medical medical_review" href="/d/html/2802.html" rel="external">"Cancer-related fatigue: Prevalence, screening, and clinical assessment", section on 'Main contributory factors'</a>.)</p><p class="headingAnchor" id="H29611072"><span class="h2">Anemia</span><span class="headingEndMark"> — </span>Anemia is a common cause of fatigue, especially in patients undergoing cancer treatment. However, in patients at the end of life, the importance of anemia as a contributor to fatigue is diminished [<a href="#rid11">11,15</a>]. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2802.html" rel="external">"Cancer-related fatigue: Prevalence, screening, and clinical assessment", section on 'Anemia'</a> and  <a class="medical medical_review" href="/d/html/2813.html" rel="external">"Cancer-related fatigue: Treatment", section on 'Anemic patients'</a>.)</p><p class="headingAnchor" id="H29611086"><span class="h2">Polypharmacy</span><span class="headingEndMark"> — </span>Medications (side effects, cumulative effects of multiple drugs, and drug-drug interactions) are an important contributor to fatigue. As examples, coadministration of opioids with other sedating medications, or drug-drug interactions between classes of medications such as anticholinergics, antihistamines, anticonvulsants, neuroleptics, opioids, central antagonists, beta blockers, diuretics, antidepressants, muscle relaxants, and benzodiazepines, may contribute to drowsiness and fatigue. Statins were found to cause fatigue in a relatively healthy non-cancer population [<a href="#rid16">16</a>] and can be safely stopped without increasing mortality for those at the end of life, with an improvement in quality of life [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/2800.html" rel="external">"Prevention and management of side effects in patients receiving opioids for chronic pain", section on 'Somnolence and mental clouding'</a> and  <a class="medical medical_review" href="/d/html/14241.html" rel="external">"Palliative care: The last hours and days of life", section on 'Eliminating non-essential medications'</a> and  <a class="medical medical_review" href="/d/html/122694.html" rel="external">"Deprescribing"</a>.)</p><p class="headingAnchor" id="H10228603"><span class="h2">Autonomic dysfunction</span><span class="headingEndMark"> — </span>Autonomic dysfunction is a common complication of advanced cancer [<a href="#rid18">18-20</a>]. This syndrome includes fatigue, postural hypotension, occasional syncope, fixed heart rate, and gastroparesis.</p><p class="headingAnchor" id="H10229820"><span class="h2">Male hypogonadism</span><span class="headingEndMark"> — </span>Hypogonadism affects at least two-thirds of males with advanced cancer. Low <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> levels in males with cancer are associated with fatigue, anorexia, depression, and insomnia [<a href="#rid21">21,22</a>]. Chronic inflammation, cachexia, chemotherapy, and medications such as opioids, <a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">megestrol acetate</a>, and glucocorticoids [<a href="#rid23">23</a>] can all contribute to hypogonadism.</p><p>Guidelines from the Endocrine Society recommend measuring <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> levels in males requiring long-term opioid therapy [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/d/html/2800.html" rel="external">"Prevention and management of side effects in patients receiving opioids for chronic pain", section on 'Neuroendocrine effects'</a> and  <a class="medical medical_review" href="/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism"</a> and  <a class="medical medical_review" href="/d/html/7460.html" rel="external">"Causes of secondary hypogonadism in males"</a>.)</p><p class="headingAnchor" id="H4310935"><span class="h2">Role of inflammatory cytokines</span><span class="headingEndMark"> — </span>Cytokines, including those used therapeutically, have been associated with fatigue and have been studied primarily in patients with cancer [<a href="#rid25">25-29</a>]. Proinflammatory cytokines can act on mood, muscle mass, cognition, and metabolic status to induce fatigue [<a href="#rid30">30,31</a>]. The inflammatory cytokines may also induce disturbance in the hypothalamic pituitary axis, affecting the levels of corticotrophin-stimulating hormone and adrenocorticotropic hormone (ACTH). These hormones, in turn, may influence adrenocorticoid hormone secretion by the adrenals [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/2802.html" rel="external">"Cancer-related fatigue: Prevalence, screening, and clinical assessment"</a> and  <a class="medical medical_review" href="/d/html/2802.html" rel="external">"Cancer-related fatigue: Prevalence, screening, and clinical assessment", section on 'Main contributory factors'</a>.)</p><p>Inflammatory cytokines may have a role in the pathophysiology of fatigue, based upon several lines of evidence:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased levels in non-oncologic conditions that are characterized by fatigue, such as chronic fatigue syndrome (CFS) [<a href="#rid25">25,26</a>]. (See  <a class="medical medical_review" href="/d/html/2740.html" rel="external">"Clinical features and diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome", section on 'Immune system differences'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The occurrence of fatigue as a major side effect of therapeutic cytokines, including interleukins, tumor necrosis factor (TNF) alpha, and interferon [<a href="#rid27">27-29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Upregulation of proinflammatory cytokines and their correlation with fatigue in cancer patients [<a href="#rid32">32-35</a>]. (See  <a class="medical medical_review" href="/d/html/2802.html" rel="external">"Cancer-related fatigue: Prevalence, screening, and clinical assessment"</a> and  <a class="medical medical_review" href="/d/html/2802.html" rel="external">"Cancer-related fatigue: Prevalence, screening, and clinical assessment", section on 'Main contributory factors'</a>.)</p><p></p><p class="headingAnchor" id="H29611093"><span class="h1">CLINICAL ASSESSMENT</span><span class="headingEndMark"> — </span>Fatigue can be classified as acute (eg, due to an infection or cardiac decompensation), in which case treatment of the condition may successfully reverse fatigue, or as chronic, in which case a multidimensional approach is likely needed.</p><p>A comprehensive history and physical examination should be undertaken to ascertain the various organ systems affected by the underlying disease as well as the impact of fatigue on activities of daily living and quality of life. Potentially reversible or treatable contributory factors should be identified.</p><p>A review of all medications (both prescribed and over the counter, including complementary/alternative therapies) is important and may reveal potential side effects, cumulative effect of multiple drugs, or drug-drug interactions that may be contributing to fatigue. If a medication is identified as being a potential contributor to fatigue, altering the dose or dosing interval may improve fatigue, or deprescribing may be more appropriate.</p><p>In all patients, assessment of the current disease status, type of treatment, and response to treatment are important components of the initial evaluation. Factors potentially related to fatigue should be assessed, including disease-specific treatments, anemia, uncontrolled pain, emotional distress, sleep disturbance, poor nutrition, electrolyte disturbances, and other comorbidities. Laboratory or radiologic evaluations may be needed. A suggested initial workup for patients with cancer-related fatigue is provided in the table (<a class="graphic graphic_table graphicRef64018" href="/d/graphic/64018.html" rel="external">table 2</a>). A more in-depth discussion of clinical assessment of fatigue in patients with cancer is provided elsewhere. (See  <a class="medical medical_review" href="/d/html/2802.html" rel="external">"Cancer-related fatigue: Prevalence, screening, and clinical assessment", section on 'Clinical assessment'</a>.)</p><p>Fatigue can be quantified by using the “0 to 10” visual analog scale and instruments, such as the Brief Fatigue Inventory, which measure not only intensity of fatigue but also functional impact, yet are not useful in determining the cause (<a class="graphic graphic_table graphicRef54810" href="/d/graphic/54810.html" rel="external">table 3</a>). Use of the simple revised Edmonton Symptom Assessment Scale (<a class="graphic graphic_table graphicRef65702" href="/d/graphic/65702.html" rel="external">table 4</a>) [<a href="#rid36">36</a>] or other multidimensional tools can provide a more comprehensive assessment of fatigue (<a class="graphic graphic_table graphicRef86228" href="/d/graphic/86228.html" rel="external">table 5</a>) [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H29611100"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Optimal management of fatigue involves aggressive treatment of reversible causes, if any are identified during the initial assessment. If a cause is not reversible or apparent, symptomatic treatment is appropriate.</p><p>The treatment of fatigue may necessitate involvement of an interdisciplinary team approach with participation by the clinician, nurse, psychiatric counselor, social worker, chaplain, physical therapist, or occupational therapist.</p><p class="headingAnchor" id="H1957600407"><span class="h2">Multimodal interventions</span><span class="headingEndMark"> — </span>Symptomatic treatment should be considered in all cases in which fatigue is not effectively managed by treatment of reversible causes. Patients may benefit from a combination of pharmacologic and nonpharmacologic interventions such as cognitive-behavioral therapy, increased physical activity, and pharmacologic therapy aimed at countering inflammation, changes in body composition, or brain function. In these cases, therapy must be individualized.</p><p>It is important to address fatigue as a subjective symptom and not as a physical syndrome; treatment should not focus solely on strategies to increase function/physical function. Lastly, patients suffer considerable distress if there is a gap between the patient’s expectation for improved physical function through intervention and the reality of actual decline in function over time; ultimately, many patients who are terminally ill will become bedridden. Measures that help adjust a patient’s expectation may include changing the focus from physical functioning to other enjoyable, non-physical activities [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H29611107"><span class="h2">Treatment of anemia</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identify and treat underlying causes</strong> – Optimal management of symptomatic anemia requires an accurate diagnosis to identify potentially remediable causes (eg, ongoing blood loss, hemolysis, or deficiency of iron, <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a>, or vitamin B12).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfusion</strong> – If a potentially treatable cause of anemia cannot be identified, red blood cell (RBC) transfusion may be an option for some patients, after reviewing the risks and potential benefits with the patient and family. Although some hospice providers may think of transfusions as “aggressive care,” patients and families or other loved ones generally do not [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1">Practice regarding RBC transfusion for treatment of fatigue in palliative care is not standardized. The decision to transfuse is multifactorial and must consider the anticipated benefits, risks, patient wishes, blood bank inventories, and alternatives to transfusion [<a href="#rid40">40</a>]. RBC transfusions may improve fatigue due to anemia in some patients, but the effect is short-lived [<a href="#rid41">41-43</a>]. In a systematic review of 12 observational before/after studies including 653 participants with advanced cancer who received RBC transfusions for treatment of fatigue or breathlessness, subjective symptom improvement was reported in 31 to 70 percent of patients [<a href="#rid42">42</a>]. Most studies reported an early response that waned by day 14. One-quarter to one-third of transfused patients died within two weeks of receiving transfusion.</p><p></p><p class="bulletIndent1">The experience with RBC transfusion in this setting was described in a multicenter prospective study involving 140 patients who received RBC transfusions in various palliative care settings (inpatient hospice/palliative care units, consultative services, and ambulatory clinics) [<a href="#rid43">43</a>]. Most patients in the study (&gt;95 percent) had advanced malignancy. The most common primary reasons for transfusion were fatigue (59 percent of patients), breathlessness (21 percent), and generalized weakness (9 percent). Approximately one-half of patients had improvement in the primary symptom following transfusion. Mild transfusion reactions occurred in 12 percent of patients.</p><p></p><p class="bulletIndent1">In making decisions regarding transfusion, clinicians should weigh the potential benefits against the known risks of transfusion, including blood-borne infection, acute transfusion reaction, transfusion-associated graft-versus-host disease, subtle immune modulation, and iron overload. (See  <a class="medical medical_review" href="/d/html/7932.html" rel="external">"Hemolytic transfusion reactions"</a> and  <a class="medical medical_review" href="/d/html/7947.html" rel="external">"Immunologic transfusion reactions"</a> and  <a class="medical medical_review" href="/d/html/7919.html" rel="external">"Transfusion-associated circulatory overload (TACO)"</a> and  <a class="medical medical_review" href="/d/html/3805.html" rel="external">"Transfusion-transmitted bacterial infection"</a> and  <a class="medical medical_review" href="/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'Transfusional iron overload'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythropoiesis-stimulating agents</strong> – Treatment with erythropoiesis-stimulating agents can be beneficial in relieving fatigue and improving quality of life in patients with chronic anemia related to cancer chemotherapy and chronic kidney disease. However, use in patients not receiving chemotherapy is not likely to be beneficial and is potentially harmful. This subject is addressed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2799.html" rel="external">"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer", section on 'Clinical use of ESAs in cancer patients'</a>.)</p><p></p><p class="headingAnchor" id="H29611114"><span class="h2">Symptom management</span></p><p class="headingAnchor" id="H10228376"><span class="h3">Pharmacologic approaches</span><span class="headingEndMark"> — </span>There are a limited number of pharmacologic agents that may have efficacy in the treatment of fatigue in palliative care populations; however, a 2016 systematic review concluded that no specific drug could be recommended for treatment of fatigue in palliative care patients due to the limited evidence [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H29611129"><span class="h4">Glucocorticoids</span><span class="headingEndMark"> — </span>Glucocorticoids may be helpful for short-term treatment of fatigue in patients who are in the terminal phases of advanced cancer [<a href="#rid45">45-53</a>]. The role of systemic glucocorticoids for cancer-related fatigue is also discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2813.html" rel="external">"Cancer-related fatigue: Treatment", section on 'Glucocorticoids'</a>.)</p><p>Unfortunately, side effects limit the long-term use of glucocorticoids. The severity of most toxicities is dose dependent. Side effects observed in some patients include infection, oral thrush, insomnia, mood swings [<a href="#rid54">54</a>], myalgia, and elevation of blood glucose. Prolonged use (for more than a month) of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> may cause gastritis (especially with concurrent use of nonsteroidal antiinflammatory drugs [NSAIDS]), hiccups, edema, muscle weakness, easy bruising, dizziness, unusual hair growth, bone loss, visceral perforation, decreased wound healing, and cardiovascular disease, including atrial fibrillation in some patients. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p>The use of glucocorticoids in the management of fatigue in terminally ill patients with diseases other than cancer is considered investigational due to the lack of well controlled studies. For this reason, we do not routinely use these agents for treatment of fatigue in palliative care patients without cancer. Glucocorticoids are most likely to be useful for conditions where there is strong inflammatory component.</p><p class="headingAnchor" id="H29611136"><span class="h4">Megestrol acetate</span><span class="headingEndMark"> — </span>Megestrol has been found to have benefit in patients with advanced cancer symptoms including anorexia-cachexia, and fatigue. In trials conducted among patients with advanced cancer and anorexia, <a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">megestrol acetate</a> improved fatigue in addition to beneficial changes in appetite and overall wellbeing when compared with placebo [<a href="#rid55">55</a>]. However, treatment with megestrol is complicated by considerable risks, including edema, thromboembolic phenomena, and increased mortality. In a meta-analysis of 10 trials involving 1106 patients with anorexia-cachexia syndrome related to cancer, acquired immunodeficiency syndrome (AIDS), or another underlying pathology, megestrol improved appetite and weight compared with placebo (33 percent of megestrol-treated patients had improved weight compared with 25 percent in the placebo group; relative risk [RR] 1.51, 95% CI 1.08-2.11) [<a href="#rid56">56</a>]. However, mortality was higher in the megestrol group (15 versus 10 percent; RR 1.42, 95% CI 1.04-1.94) and treatment was associated with increased rates of thromboembolic events (19 versus 10 percent; RR 1.84, 95% CI 1.07-3.18) and edema (14 versus 10 percent; RR 1.36, 95% CI 1.07-1.72). Therefore, in clinical practice, megestrol acetate should be considered only in select advanced cancer patient populations with persistent cancer-related fatigue and rapid weight loss due to cachexia, with careful monitoring for side effects. (See  <a class="medical medical_review" href="/d/html/2816.html" rel="external">"Management of cancer anorexia/cachexia", section on 'Progesterone analogs'</a>.)</p><p class="headingAnchor" id="H29611151"><span class="h4">Psychostimulants</span><span class="headingEndMark"> — </span>Both fatigue and depression in patients receiving palliative care can be treated with the psychostimulants such as <a class="drug drug_general" data-topicid="9341" href="/d/drug information/9341.html" rel="external">dextroamphetamine</a>, <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a>, pemoline (not available in the United States), <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a> [<a href="#rid57">57,58</a>], or <a class="drug drug_general" data-topicid="10157" href="/d/drug information/10157.html" rel="external">modafinil</a>. Psychostimulants act rapidly and are generally well tolerated and safe. However, they should be used with caution in patients with heart disease or delirium.</p><p>All of the available data addressing the role of psychostimulants in management of fatigue patients with serious and/or life-threatening illness are in patients with cancer, in whom the benefit has been best shown for <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a>, <a class="drug drug_general" data-topicid="10157" href="/d/drug information/10157.html" rel="external">modafinil</a>, and <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a> for treatment of severe fatigue; the benefit is less certain in patients with mild to moderate fatigue. (See  <a class="medical medical_review" href="/d/html/2813.html" rel="external">"Cancer-related fatigue: Treatment"</a> and  <a class="medical medical_review" href="/d/html/2813.html" rel="external">"Cancer-related fatigue: Treatment", section on 'Psychostimulants and other wakefulness agents'</a>.)</p><p>The use of psychostimulants in the management of fatigue in terminally ill patients with diseases other than cancer is considered investigational. However, a trial of psychostimulants such as <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a>, <a class="drug drug_general" data-topicid="10157" href="/d/drug information/10157.html" rel="external">modafinil</a>, or <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a> is reasonable for patients without cancer with severe fatigue who do not respond to or have a contraindication to other established therapies such as exercise or cognitive-behavioral therapy [<a href="#rid59">59-63</a>].</p><p class="headingAnchor" id="H29612223"><span class="h4">Testosterone for hypogonadal males</span><span class="headingEndMark"> — </span>Hypogonadism affects two-thirds of males with advanced cancer; low <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> levels in males with cancer are associated with fatigue, anorexia, depression, and insomnia. (See <a class="local">'Male hypogonadism'</a> above.)</p><p><a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">Testosterone</a> replacement improves quality of life and diminishes fatigue for hypogonadal males with non-cancer conditions; however, guidelines specifically recommend against testosterone supplementation in males with active breast or prostate cancer given concerns for acceleration of disease growth [<a href="#rid24">24</a>]. Relative contraindications, such as an undiagnosed prostate nodule or an elevated serum prostate-specific antigen (PSA) level, may be reconsidered on an individual basis depending on the overall prognosis [<a href="#rid23">23</a>]. A more in-depth discussion about contraindications to testosterone replacement therapy and an overview of monitoring during therapy are provided elsewhere. (See  <a class="medical medical_review" href="/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism", section on 'Contraindications to use'</a> and  <a class="medical medical_review" href="/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism", section on 'Monitoring'</a>.)</p><p>The use of <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> in males with hypogonadism and cancer related fatigue is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2813.html" rel="external">"Cancer-related fatigue: Treatment", section on 'Testosterone for hypogonadal men'</a>.)</p><p class="headingAnchor" id="H29612230"><span class="h4">Complementary medicines</span><span class="headingEndMark"> — </span>For patients who have moderate to severe fatigue who are undergoing active anticancer therapy, American ginseng may be reasonable as long as the patient is not receiving drugs that may interact unfavorably with ginseng, such as anticoagulants. On the other hand, benefit is less clear for Asian ginseng (<em>Panax ginseng</em>) [<a href="#rid64">64,65</a>]. Ginseng for cancer-related fatigue is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2813.html" rel="external">"Cancer-related fatigue: Treatment", section on 'Ginseng and guarana'</a>.)</p><p class="headingAnchor" id="H29611172"><span class="h3">Nonpharmacologic approaches</span></p><p class="headingAnchor" id="H29611180"><span class="h4">Exercise</span><span class="headingEndMark"> — </span>Physical activity is important to maintain a sense of wellbeing and to enhance quality of life [<a href="#rid66">66</a>]. Most palliative care patients experience multiple symptoms, such as fatigue, pain, dyspnea, and nausea, that may all contribute to reduced physical activity, or even inactivity, and thereby reduced physical functioning. Exercise rehabilitation during or after curative or life-prolonging treatment is considered an effective means of restoring physical and psychological function [<a href="#rid67">67,68</a>].</p><p>The benefits of exercise in terms of improving physical performance have been shown in many trials conducted in patients with advanced cancer, although benefit in terms of fatigue has been more difficult to show. As an example, in a large randomized control study of 231 patients with incurable cancer and a life expectancy of three months to two years, physical exercise (60 minutes twice a week for eight weeks) provided significant improvement in physical performance as assessed by a hand grip strength test and the shuttle walk test, whereas fatigue, the predefined primary endpoint, was not significantly reduced [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/d/html/2813.html" rel="external">"Cancer-related fatigue: Treatment", section on 'Exercise'</a>.)</p><p>Additional randomized controlled trials are required in palliative care settings to assess the overall efficacy of exercise [<a href="#rid70">70</a>]. However, moderate exercise is a reasonable recommendation, if patients are able to tolerate it.</p><p class="headingAnchor" id="H23013425"><span class="h4">Yoga</span><span class="headingEndMark"> — </span>Yoga may have benefit in patients with cancer-related fatigue and is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2813.html" rel="external">"Cancer-related fatigue: Treatment", section on 'Yoga'</a>.)</p><p class="headingAnchor" id="H3144375652"><span class="h4">Qigong/tai chi</span><span class="headingEndMark"> — </span>Qigong is a traditional Chinese exercise therapy commonly used for the treatment of cancer-related fatigue. This is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2813.html" rel="external">"Cancer-related fatigue: Treatment", section on 'Tai chi/qigong'</a>.)</p><p class="headingAnchor" id="H23013530"><span class="h4">Sleep hygiene</span><span class="headingEndMark"> — </span>In patients with advanced cancer or other life-limiting disease states, it is common to have multiple symptoms occurring simultaneously; hence, it is difficult to determine that sleep disturbance is the sole causative mechanism for fatigue, or if fatigue is contributing to sleep disturbance.<strong> </strong>Sleep disturbance may be influenced by numerous factors including daytime naps, pain, depression, anxiety, medication, sleep interruption because of sleep apnea, nocturia or hot flashes, and evening food and/or beverage intake.</p><p>Few studies have evaluated sleep interventions to manage fatigue in advanced cancer and other life-limiting illnesses; the results are conflicting. Cognitive-behavioral therapy and stress reduction may help. Other suggestions for improving sleep patterns include taking a warm bath or drinking a glass of warm milk prior to bedtime, avoiding caffeinated beverages following dinner, emptying the bladder just before going to bed, and scheduling naps earlier in the day (<a class="graphic graphic_table graphicRef50224" href="/d/graphic/50224.html" rel="external">table 6</a>). Some patients require medications to help them sleep. (See  <a class="medical medical_review" href="/d/html/89189.html" rel="external">"Insomnia in palliative care"</a>.)</p><p class="headingAnchor" id="H29611187"><span class="h4">Behavioral and psychosocial interventions</span><span class="headingEndMark"> — </span>Cognitive-behavioral and psychosocial interventions (including mindfulness-based stress reduction) have been found to be an effective modality for the treatment of cancer-related fatigue and are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2813.html" rel="external">"Cancer-related fatigue: Treatment", section on 'Cognitive-behavioral interventions'</a>.)</p><p class="headingAnchor" id="H907347144"><span class="h4">Acupuncture</span><span class="headingEndMark"> — </span>Acupuncture may have benefit in cancer-related fatigue and is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2813.html" rel="external">"Cancer-related fatigue: Treatment", section on 'Acupuncture'</a>.)</p><p class="headingAnchor" id="H4261457741"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119531.html" rel="external">"Society guideline links: Palliative care"</a>.)</p><p class="headingAnchor" id="H29611194"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Significance</strong> – Fatigue (asthenia, weakness) is a common symptom in palliative care that affects the quality of life. Fatigue should be distinguished from other common presentations in palliative care, including depression, delirium, drowsiness, demoralization, psychomotor retardation, and muscle weakness. (See <a class="local">'Definition'</a> above and <a class="local">'Prevalence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes</strong> – In palliative care patients, acute fatigue may be due to a potentially reversible medical condition (eg, cardiac decompensation, infection), while chronic fatigue is more likely to have multiple contributing causes (<a class="graphic graphic_table graphicRef86231" href="/d/graphic/86231.html" rel="external">table 7</a>) (see <a class="local">'Etiology'</a> above). Anemia is a particularly important contributor in patients undergoing cancer treatment but is a less common contributor to fatigue in patients nearing the end of life. (See <a class="local">'Multiple causes likely'</a> above and <a class="local">'Anemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Measurement</strong> – The intensity of fatigue can be assessed using the “0 to 10” visual analog scale or instruments, such as the Brief Fatigue Inventory, which measure not only intensity but also functional impact (<a class="graphic graphic_table graphicRef54810" href="/d/graphic/54810.html" rel="external">table 3</a>). (See <a class="local">'Clinical assessment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment</strong> – A comprehensive history and physical examination is indicated to identify potentially reversible etiologies. (<a class="graphic graphic_table graphicRef86231" href="/d/graphic/86231.html" rel="external">table 7</a>). A review of all medications, both prescription and over the counter, is particularly important to identify side effects and potential drug-drug interactions that may be contributing to fatigue. Simply altering the dose or dosing interval may substantially improve fatigue. (See <a class="local">'Polypharmacy'</a> above and <a class="local">'Clinical assessment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of anemia</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Identify and treat underlying causes</strong> – Optimal management of symptomatic anemia requires an accurate diagnosis to identify potentially remediable causes (eg, ongoing blood loss, hemolysis, or deficiency of iron, <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a>, or vitamin B12). (See  <a class="medical medical_review" href="/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults"</a> and  <a class="medical medical_review" href="/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults"</a> and  <a class="medical medical_review" href="/d/html/7140.html" rel="external">"Causes of anemia in patients with cancer"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transfusion</strong> – If a potentially treatable cause of anemia cannot be identified, red blood cell (RBC) transfusion may be an option after weighing the anticipated benefits, risks, patient wishes, blood bank inventories, and alternatives to transfusion. RBC transfusions may improve fatigue due to anemia in some patients, but the effect is short-lived. (See <a class="local">'Treatment of anemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Erythropoiesis-stimulating agents</strong> – Erythropoiesis-stimulating agents may be beneficial in relieving fatigue in patients with chronic anemia related to cancer chemotherapy or chronic kidney disease. However, use in other populations is not likely to be beneficial and is potentially harmful. This subject is addressed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2799.html" rel="external">"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer", section on 'Clinical use of ESAs in cancer patients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptomatic management</strong> – If a specific cause of fatigue cannot be identified, our suggested approach to symptomatic management is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We provide information on coping strategies that conserve energy (<a class="graphic graphic_table graphicRef73183" href="/d/graphic/73183.html" rel="external">table 8</a> and <a class="graphic graphic_table graphicRef53415" href="/d/graphic/53415.html" rel="external">table 9</a>) and information on good sleep hygiene (<a class="graphic graphic_table graphicRef50224" href="/d/graphic/50224.html" rel="external">table 6</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">Megestrol acetate</a> has modest benefits on appetite and weight, but it has considerable side effects and may increase mortality. Use of this agent is generally limited to select advanced cancer patient populations with persistent cancer-related cachexia. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/2816.html" rel="external">"Management of cancer anorexia/cachexia", section on 'Progesterone analogs'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with opioid-related sedation and those with severe fatigue who do not respond to or cannot participate in exercise or cognitive-behavioral interventions, we suggest a trial of pharmacotherapy with <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a>, <a class="drug drug_general" data-topicid="10157" href="/d/drug information/10157.html" rel="external">modafinil</a>, <a class="drug drug_general" data-topicid="9260" href="/d/drug information/9260.html" rel="external">armodafinil</a>, or <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, the role of psychostimulants is not well defined, particularly for patients with serious and/or life-threatening illnesses other than cancer. Thus, some patients may reasonably choose to forego pharmacotherapy and focus instead on nonpharmacologic approaches. (See <a class="local">'Psychostimulants'</a> above and  <a class="medical medical_review" href="/d/html/2813.html" rel="external">"Cancer-related fatigue: Treatment", section on 'Psychostimulants and other wakefulness agents'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complementary medicine and nonpharmacologic approaches are available and may include ginseng, exercise, yoga, and cognitive-behavioral therapy, including mindfulness-based stress reduction [<a href="#rid71">71,72</a>]. (See <a class="local">'Complementary medicines'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Stone P, Richards M, Hardy J. Fatigue in patients with cancer. Eur J Cancer 1998; 34:1670.</a></li><li class="breakAll">National Comprehensive Cancer Network. NCCN guidelines: Treatment by cancer type. Available at: https://www.nccn.org/guidelines/category_1 (Accessed on April 23, 2019).</li><li><a class="nounderline abstract_t">Robinson S, Kissane DW, Brooker J, Burney S. A systematic review of the demoralization syndrome in individuals with progressive disease and cancer: a decade of research. J Pain Symptom Manage 2015; 49:595.</a></li><li><a class="nounderline abstract_t">Vehling S, Oechsle K, Koch U, Mehnert A. Receiving palliative treatment moderates the effect of age and gender on demoralization in patients with cancer. PLoS One 2013; 8:e59417.</a></li><li><a class="nounderline abstract_t">Cella D, Davis K, Breitbart W, et al. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 2001; 19:3385.</a></li><li><a class="nounderline abstract_t">Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000; 5:353.</a></li><li><a class="nounderline abstract_t">Stone P, Richardson A, Ream E, et al. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol 2000; 11:971.</a></li><li><a class="nounderline abstract_t">Piper BF, Cella D. Cancer-related fatigue: definitions and clinical subtypes. J Natl Compr Canc Netw 2010; 8:958.</a></li><li><a class="nounderline abstract_t">Vogl D, Rosenfeld B, Breitbart W, et al. Symptom prevalence, characteristics, and distress in AIDS outpatients. J Pain Symptom Manage 1999; 18:253.</a></li><li><a class="nounderline abstract_t">Kutner JS, Kassner CT, Nowels DE. Symptom burden at the end of life: hospice providers' perceptions. J Pain Symptom Manage 2001; 21:473.</a></li><li><a class="nounderline abstract_t">Stone P, Richards M, A'Hern R, Hardy J. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 2000; 11:561.</a></li><li><a class="nounderline abstract_t">Respini D, Jacobsen PB, Thors C, et al. The prevalence and correlates of fatigue in older cancer patients. Crit Rev Oncol Hematol 2003; 47:273.</a></li><li><a class="nounderline abstract_t">Hwang SS, Chang VT, Rue M, Kasimis B. Multidimensional independent predictors of cancer-related fatigue. J Pain Symptom Manage 2003; 26:604.</a></li><li><a class="nounderline abstract_t">Cherian D, Paladugu S, Pathikonda M, Parkman HP. Fatigue: a prevalent symptom in gastroparesis. Dig Dis Sci 2012; 57:2088.</a></li><li><a class="nounderline abstract_t">Munch TN, Zhang T, Willey J, et al. The association between anemia and fatigue in patients with advanced cancer receiving palliative care. J Palliat Med 2005; 8:1144.</a></li><li><a class="nounderline abstract_t">Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med 2012; 172:1180.</a></li><li><a class="nounderline abstract_t">Kutner JS, Blatchford PJ, Taylor DH Jr, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med 2015; 175:691.</a></li><li><a class="nounderline abstract_t">Coumbe BGT, Groarke JD. Cardiovascular Autonomic Dysfunction in Patients with Cancer. Curr Cardiol Rep 2018; 20:69.</a></li><li><a class="nounderline abstract_t">Stone CA, Kenny RA, Nolan B, Lawlor PG. Autonomic dysfunction in patients with advanced cancer; prevalence, clinical correlates and challenges in assessment. BMC Palliat Care 2012; 11:3.</a></li><li><a class="nounderline abstract_t">Bruera E, Chadwick S, Fox R, et al. Study of cardiovascular autonomic insufficiency in advanced cancer patients. Cancer Treat Rep 1986; 70:1383.</a></li><li><a class="nounderline abstract_t">Del Fabbro E, Hui D, Nooruddin ZI, et al. Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report. J Pain Symptom Manage 2010; 39:1016.</a></li><li><a class="nounderline abstract_t">Dev R, Hui D, Del Fabbro E, et al. Association between hypogonadism, symptom burden, and survival in male patients with advanced cancer. Cancer 2014; 120:1586.</a></li><li><a class="nounderline abstract_t">Dev R, Bruera E, Del Fabbro E. When and when not to use testosterone for palliation in cancer care. Curr Oncol Rep 2014; 16:378.</a></li><li><a class="nounderline abstract_t">Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95:2536.</a></li><li><a class="nounderline abstract_t">Cannon JG, Angel JB, Abad LW, et al. Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome. J Clin Immunol 1997; 17:253.</a></li><li><a class="nounderline abstract_t">Moss RB, Mercandetti A, Vojdani A. TNF-alpha and chronic fatigue syndrome. J Clin Immunol 1999; 19:314.</a></li><li><a class="nounderline abstract_t">Sarna GP, Figlin RA, Pertcheck M, et al. Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: clinical results. J Biol Response Mod 1989; 8:16.</a></li><li><a class="nounderline abstract_t">Eskander ED, Harvey HA, Givant E, Lipton A. Phase I study combining tumor necrosis factor with interferon-alpha and interleukin-2. Am J Clin Oncol 1997; 20:511.</a></li><li><a class="nounderline abstract_t">Veldhuis GJ, Willemse PH, Sleijfer DT, et al. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J Clin Oncol 1995; 13:2585.</a></li><li><a class="nounderline abstract_t">Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. Lancet 2003; 362:640.</a></li><li><a class="nounderline abstract_t">Lee BN, Dantzer R, Langley KE, et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation 2004; 11:279.</a></li><li><a class="nounderline abstract_t">Inagaki M, Isono M, Okuyama T, et al. Plasma interleukin-6 and fatigue in terminally ill cancer patients. J Pain Symptom Manage 2008; 35:153.</a></li><li><a class="nounderline abstract_t">Adler HL, McCurdy MA, Kattan MW, et al. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999; 161:182.</a></li><li><a class="nounderline abstract_t">Collado-Hidalgo A, Bower JE, Ganz PA, et al. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res 2006; 12:2759.</a></li><li><a class="nounderline abstract_t">Saligan LN, Olson K, Filler K, et al. The biology of cancer-related fatigue: a review of the literature. Support Care Cancer 2015; 23:2461.</a></li><li><a class="nounderline abstract_t">Watanabe SM, Nekolaichuk C, Beaumont C, et al. A multicenter study comparing two numerical versions of the Edmonton Symptom Assessment System in palliative care patients. J Pain Symptom Manage 2011; 41:456.</a></li><li><a class="nounderline abstract_t">Dittner AJ, Wessely SC, Brown RG. The assessment of fatigue: a practical guide for clinicians and researchers. J Psychosom Res 2004; 56:157.</a></li><li><a class="nounderline abstract_t">Yennurajalingam S, Bruera E. Palliative management of fatigue at the close of life: "it feels like my body is just worn out". JAMA 2007; 297:295.</a></li><li><a class="nounderline abstract_t">Meystre CJ, Burley NM, Ahmedzai S. What investigations and procedures do patients in hospices want? Interview based survey of patients and their nurses. BMJ 1997; 315:1202.</a></li><li><a class="nounderline abstract_t">Raval JS. Transfusion as a Palliative Strategy. Curr Oncol Rep 2019; 21:92.</a></li><li><a class="nounderline abstract_t">Mercadante S, Ferrera P, Villari P, et al. Effects of red blood cell transfusion on anemia-related symptoms in patients with cancer. J Palliat Med 2009; 12:60.</a></li><li><a class="nounderline abstract_t">Preston NJ, Hurlow A, Brine J, Bennett MI. Blood transfusions for anaemia in patients with advanced cancer. Cochrane Database Syst Rev 2012; :CD009007.</a></li><li><a class="nounderline abstract_t">To THM, LeBlanc TW, Eastman P, et al. The Prospective Evaluation of the Net Effect of Red Blood Cell Transfusions in Routine Provision of Palliative Care. J Palliat Med 2017; 20:1152.</a></li><li><a class="nounderline abstract_t">Mücke M, Mochamat, Cuhls H, et al. Pharmacological treatments for fatigue associated with palliative care: executive summary of a Cochrane Collaboration systematic review. J Cachexia Sarcopenia Muscle 2016; 7:23.</a></li><li><a class="nounderline abstract_t">Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14:1756.</a></li><li><a class="nounderline abstract_t">Hardy JR, Rees E, Ling J, et al. A prospective survey of the use of dexamethasone on a palliative care unit. Palliat Med 2001; 15:3.</a></li><li><a class="nounderline abstract_t">Paulsen O, Klepstad P, Rosland JH, et al. Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. J Clin Oncol 2014; 32:3221.</a></li><li><a class="nounderline abstract_t">Yennurajalingam S, Frisbee-Hume S, Palmer JL, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 2013; 31:3076.</a></li><li><a class="nounderline abstract_t">Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985; 69:751.</a></li><li><a class="nounderline abstract_t">Fainsinger RL, Spachynski K, Hanson J, Bruera E. Symptom control in terminally ill patients with malignant bowel obstruction (MBO). J Pain Symptom Manage 1994; 9:12.</a></li><li><a class="nounderline abstract_t">Ettinger AB, Portenoy RK. The use of corticosteroids in the treatment of symptoms associated with cancer. J Pain Symptom Manage 1988; 3:99.</a></li><li><a class="nounderline abstract_t">Bruera E, Moyano JR, Sala R, et al. Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manage 2004; 28:381.</a></li><li class="breakAll">Yennurajalingam S, Frisbee-Hume S, Delgado-Guay MO, et al. Dexamethasone (DM) for cancer-related fatigue: A double-blinded, randomized, placebo-controlled trial. Abstract, ASCO Annual Meeting I, Chicago, IL, June 2012.</li><li><a class="nounderline abstract_t">Akid I, Nesbit S, Nanavati J, et al. Prevention of Steroid-Induced Neuropsychiatric Complications With Neuroleptic Drugs: A Review. Am J Hosp Palliat Care 2022; 39:472.</a></li><li><a class="nounderline abstract_t">Maltoni M, Nanni O, Scarpi E, et al. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. Ann Oncol 2001; 12:289.</a></li><li><a class="nounderline abstract_t">Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, et al. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2013; :CD004310.</a></li><li><a class="nounderline abstract_t">Correa-Morales JE, Cuellar-Valencia L, Mantilla-Manosalva N, et al. Cancer and Non-cancer Fatigue Treated With Bupropion: A Systematic Review. J Pain Symptom Manage 2023; 65:e21.</a></li><li><a class="nounderline abstract_t">Salehifar E, Azimi S, Janbabai G, et al. Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial. BMC Cancer 2020; 20:158.</a></li><li><a class="nounderline abstract_t">Bruera E, Chadwick S, Brenneis C, et al. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep 1987; 71:67.</a></li><li><a class="nounderline abstract_t">Bruera E, Miller MJ, Macmillan K, Kuehn N. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain 1992; 48:163.</a></li><li><a class="nounderline abstract_t">Bruera E, Fainsinger R, MacEachern T, Hanson J. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain 1992; 50:75.</a></li><li><a class="nounderline abstract_t">Webster L, Andrews M, Stoddard G. Modafinil treatment of opioid-induced sedation. Pain Med 2003; 4:135.</a></li><li><a class="nounderline abstract_t">Wilwerding MB, Loprinzi CL, Mailliard JA, et al. A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Cancer 1995; 3:135.</a></li><li><a class="nounderline abstract_t">Yennurajalingam S, Tannir NM, Williams JL, et al. A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients With Advanced Cancer. J Natl Compr Canc Netw 2017; 15:1111.</a></li><li class="breakAll">Kim YH, Lim, YL, Cho JY, et al. Korean red ginseng to improve cancer-related fatigue in colorectal cancer patients with FOLFOX chemotherapy: A randomized, double-blind, placebo-controlled, parallel, multicenter trial, NCT02039635. Abstract, ASCO Annual Meeting I, Chicago, IL, June 2017.</li><li><a class="nounderline abstract_t">Cohen SR, Leis A. What determines the quality of life of terminally ill cancer patients from their own perspective? J Palliat Care 2002; 18:48.</a></li><li><a class="nounderline abstract_t">Oldervoll LM, Loge JH, Paltiel H, et al. The effect of a physical exercise program in palliative care: A phase II study. J Pain Symptom Manage 2006; 31:421.</a></li><li><a class="nounderline abstract_t">Mayo NE, Moriello C, Scott SC, et al. Pedometer-facilitated walking intervention shows promising effectiveness for reducing cancer fatigue: a pilot randomized trial. Clin Rehabil 2014; 28:1198.</a></li><li><a class="nounderline abstract_t">Oldervoll LM, Loge JH, Lydersen S, et al. Physical exercise for cancer patients with advanced disease: a randomized controlled trial. Oncologist 2011; 16:1649.</a></li><li><a class="nounderline abstract_t">Wagner LI, Cella D. Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer 2004; 91:822.</a></li><li><a class="nounderline abstract_t">Bower JE, Bak K, Berger A, et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation. J Clin Oncol 2014; 32:1840.</a></li><li><a class="nounderline abstract_t">Pearson EJ, Morris ME, McKinstry CE. Cancer-related fatigue: appraising evidence-based guidelines for screening, assessment and management. Support Care Cancer 2016; 24:3935.</a></li></ol></div><div id="topicVersionRevision">Topic 14239 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9893650" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Fatigue in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9893650" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Fatigue in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25131888" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A systematic review of the demoralization syndrome in individuals with progressive disease and cancer: a decade of research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23555030" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Receiving palliative treatment moderates the effect of age and gender on demoralization in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11454886" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11040270" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11038033" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20870639" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cancer-related fatigue: definitions and clinical subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10534965" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Symptom prevalence, characteristics, and distress in AIDS outpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11397605" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Symptom burden at the end of life: hospice providers' perceptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10907949" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12962901" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The prevalence and correlates of fatigue in older cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12850643" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Multidimensional independent predictors of cancer-related fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22669206" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Fatigue: a prevalent symptom in gastroparesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16351527" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The association between anemia and fatigue in patients with advanced cancer receiving palliative care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22688574" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25798575" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29971575" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cardiovascular Autonomic Dysfunction in Patients with Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22379978" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Autonomic dysfunction in patients with advanced cancer; prevalence, clinical correlates and challenges in assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3791252" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Study of cardiovascular autonomic insufficiency in advanced cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20457506" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24577665" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Association between hypogonadism, symptom burden, and survival in male patients with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24510740" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : When and when not to use testosterone for palliation in cancer care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20525905" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9168406" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10535608" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : TNF-alpha and chronic fatigue syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2784163" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: clinical results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9345339" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Phase I study combining tumor necrosis factor with interferon-alpha and interleukin-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7595711" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12944066" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Assessment and management of cancer-related fatigue in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15316238" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A cytokine-based neuroimmunologic mechanism of cancer-related symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18082358" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Plasma interleukin-6 and fatigue in terminally ill cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10037394" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16675568" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Inflammatory biomarkers for persistent fatigue in breast cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25975676" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The biology of cancer-related fatigue: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20832987" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A multicenter study comparing two numerical versions of the Edmonton Symptom Assessment System in palliative care patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15016573" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The assessment of fatigue: a practical guide for clinicians and researchers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17227981" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Palliative management of fatigue at the close of life: "it feels like my body is just worn out".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9393223" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : What investigations and procedures do patients in hospices want? Interview based survey of patients and their nurses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31471735" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Transfusion as a Palliative Strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19284264" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effects of red blood cell transfusion on anemia-related symptoms in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336857" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Blood transfusions for anaemia in patients with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28598239" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The Prospective Evaluation of the Net Effect of Red Blood Cell Transfusions in Routine Provision of Palliative Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27066315" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pharmacological treatments for fatigue associated with palliative care: executive summary of a Cochrane Collaboration systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8656243" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11212465" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A prospective survey of the use of dexamethasone on a palliative care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25002731" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23897970" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2410117" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7513332" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Symptom control in terminally ill patients with malignant bowel obstruction (MBO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3282015" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The use of corticosteroids in the treatment of symptoms associated with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15471656" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15471656" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34387114" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prevention of Steroid-Induced Neuropsychiatric Complications With Neuroleptic Drugs: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11332139" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23543530" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Megestrol acetate for treatment of anorexia-cachexia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36198335" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Cancer and Non-cancer Fatigue Treated With Bupropion: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32106832" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3791269" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Methylphenidate associated with narcotics for the treatment of cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1589233" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1381072" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12873263" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Modafinil treatment of opioid-induced sedation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7539701" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28874596" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients With Advanced Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28874596" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients With Advanced Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12001403" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : What determines the quality of life of terminally ill cancer patients from their own perspective?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16716872" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The effect of a physical exercise program in palliative care: A phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24917586" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pedometer-facilitated walking intervention shows promising effectiveness for reducing cancer fatigue: a pilot randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21948693" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Physical exercise for cancer patients with advanced disease: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15238987" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Fatigue and cancer: causes, prevalence and treatment approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24733803" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27116014" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cancer-related fatigue: appraising evidence-based guidelines for screening, assessment and management.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
